Orchid Chemicals & Pharmaceuticals Ltd : Orchid Pharma registers 6% growth in FY12. Long-term supply contracts continue to add value to earnings. – 4-traders (press release)

This includes 8 Para IV FTF (First-To-File) filings. The break-up of the total ANDA filings is 13 in the Cephalosporins space and 30 in the NPNC (Non-penicillin, Non-cephalosporin) space. On the approvals front too, Orchid made good progress. The count of …

Leave a Reply

Your email address will not be published.